Dana Zhang

Dr. Dana Zhang has 20+ years’ experience in Pharma Industry including medical, marketing, commercial management, business development and regulatory affair; she has worked in rare diseases and orphan drug market since 2004.

Before joining Kira, Dana served as General Manager of Greater China in Alexion with profound knowledge of complement system for 9 years (2011-2019); responsible for all aspects of commercial operations strategy and P&L management in Taiwan, Hong Kong and China. Previous to Alexion, Dana was Head of Business Development in Celgene China for Revlimid and Vidaza; Country Manager of Actelion China and led the successful launch of Tracleer with clinical trial waiver. She had led the establishment of 4 foreign Biopharma entities in China (Alexion, Celgene, Actelion and Genzyme). Her earlier career included extensive experience in Medical and Marketing for Roche Shanghai in Renal Transplant Business Unit (2000-2003).

Before Dana’s highly successful career in the Pharma industry, she was a Clinical Nephrologist in Renji Hospital, Shanghai Jiao Tong University and holds a Master Degree in Clinical Medicine, Shanghai Second Medical University.